摘要
嵌合抗原受体(CAR)-T细胞疗法在复发难治性血液恶性肿瘤中的应用已经取得了令人鼓舞的临床疗效,但在靶向杀伤特异性、有效性以及安全性等方面均存在一定的挑战。近年来,国内外研究人员为解决CAR-T细胞疗法所存在的问题在CAR基因结构优化方面进行了深入的研究。本文主要阐述CAR基因中胞外结构域、跨膜区和胞内结构域的优化以及新型CAR基因设计,为进一步提高CAR-T细胞疗法的安全性和有效性提供新信息。
Although chimeric antigen receptor(CAR)-T therapy has produced remarkable clinical responses for patients with relapsed or refractory hematological malignancies,setbacks were experienced,including antigen escape and heterogeneity,its efficacy and safety issues.In recent years,researchers at home and abroad are addressing the current obstacles by digging deeply into structural optimization of CAR gene in order to solve the problems of CAR-T cell therapy.In this review,we mainly illustrate the ectodomain structure,transmemberane domain,and endodomain structure,and new designs which promote persistence of CAR-T cells in vivo,so as to provide new ideas for improving the safety and the efficacy of CAR-T cell therapy.
作者
应培挺
翁雯雯
汤永民
YING Pei-Ting;WENG Wen-Wen;TANG Yong-Min(Department of Hematology-Oncology,The Childrens’Hospital,Zhejiang University School of Medicine,Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province,National Clinical Research Center for Child Health,Hangzhou 310003,Zhejiang Province,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2022年第6期1902-1906,共5页
Journal of Experimental Hematology
基金
国家自然科学基金(81770202,81470304)
浙江省科技厅重点研发项目(2019C03032)
浙江省小儿白血病诊治技术研究中心专项基金(JBZX-201904)。
关键词
嵌合抗原受体T细胞
结构优化
安全性
有效性
chimeric antigen receptor T cell
structural optimization
safety
efficacy